The Investor
31 Mar 2026, 13:41
Lilly to acquire Centessa Pharmaceuticals in $6.3 billion deal to expand neuroscience portfolio
31 March 2026 — Eli Lilly and Company announced a definitive agreement to acquire Centessa Pharmaceuticals to strengthen its capabilities in sleep-wake disorder treatments.
The transaction values Centessa at approximately $6.3 billion upfront, with additional contingent payments of up to $1.5 billion tied to regulatory milestones, bringing the potential total to $47 per share.
Centessa’s pipeline focuses on orexin receptor 2 (OX2R) agonists, including its lead candidate cleminorexton, which has shown promising results in treating conditions such as narcolepsy and idiopathic hypersomnia.
Lilly stated the acquisition will expand its neuroscience portfolio and accelerate development of therapies targeting sleep-wake disorders and related neurological conditions. The deal is expected to close in the third quarter of 2026, subject to shareholder and regulatory approvals.
PRNewswire
31 March 2026 — Eli Lilly and Company announced a definitive agreement to acquire Centessa Pharmaceuticals to strengthen its capabilities in sleep-wake disorder treatments.
The transaction values Centessa at approximately $6.3 billion upfront, with additional contingent payments of up to $1.5 billion tied to regulatory milestones, bringing the potential total to $47 per share.
Centessa’s pipeline focuses on orexin receptor 2 (OX2R) agonists, including its lead candidate cleminorexton, which has shown promising results in treating conditions such as narcolepsy and idiopathic hypersomnia.
Lilly stated the acquisition will expand its neuroscience portfolio and accelerate development of therapies targeting sleep-wake disorders and related neurological conditions. The deal is expected to close in the third quarter of 2026, subject to shareholder and regulatory approvals.
PRNewswire